Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LCM
MCID: MNT001
MIFTS: 69

Mantle Cell Lymphoma (LCM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mantle Cell Lymphoma

About this section

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 12 74 52 58 36 29 6 15 37 17 32
Lcm 58 3
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 71
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 71
Lymphoma, Mantle Cell 52
Lymphoma, Mantle-Cell 43
Mantle Zone Lymphoma 58
Lymphoma Mantle-Cell 54
Mcl 58

Characteristics:

Orphanet epidemiological data:

58
mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050746
KEGG 36 H01464
MeSH 43 D020522
ICD10 32 C83.1
MESH via Orphanet 44 D020522
ICD10 via Orphanet 33 C83.1
UMLS via Orphanet 72 C0555202
Orphanet 58 ORPHA52416
UMLS 71 C0334634 C0555202
Sources

Summaries for Mantle Cell Lymphoma

About this section
CDC : 3 Lymphocytic choriomeningitis, or LCM, is a rodent-borne viral infectious disease caused by lymphocytic choriomeningitis virus (LCMV), a member of the family Arenaviridae, that was initially isolated in 1933. The primary host of LCMV is the common house mouse, Mus musculus. Infection in house mouse populations may vary by geographic location, though it is estimated that 5% of house mice throughout the United States carry LCMV and are able to transmit virus for the duration of their lives without showing any sign of illness. Other types of rodents, such as hamsters, are not the natural reservoirs but can become infected with LCMV from wild mice at the breeder, in the pet store, or home environment. Humans are more likely to contract LCMV from house mice, but infections from pet rodents have also been reported.

MalaCards based summary : Mantle Cell Lymphoma, also known as lcm, is related to follicular lymphoma and lymphoma. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human cytomegalovirus infection. The drugs Orange and Cefepime have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are lymphadenopathy and b-cell lymphoma

Disease Ontology : 12 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

NIH Rare Diseases : 52 Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system ). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. In these situations, treatment must be intensive since MCL can become life threatening within a short period of time. MCL accounts for 6% of all NHL's and is mostly found in males during their early 60s.

KEGG : 36 Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma (NHL) and it accounts for about 6% of all NHL cases. Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. The molecular hallmark and putative initiating oncogenic event in MCL is the t(11;14)(q13;q32) translocation resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course.

Wikipedia : 74 Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL), comprising about 6% of NHL cases.... more...

Sources

Related Diseases for Mantle Cell Lymphoma

About this section

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 505)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 33.7 MYC MIR17 MIR155 IGH EZH2 CD5
2 lymphoma 32.7 TP53 MYC MDM2 GAS5 EZH2 CD5
3 lymphoma, non-hodgkin, familial 32.4 TP53 MYC MIR17 MIR155 MDM2 IGH
4 marginal zone b-cell lymphoma 32.4 CD5 CCND1 BTK BCL6
5 leukemia, chronic lymphocytic 32.3 TP53 MYC MIR17 MIR16-1 MIR155 MDM2
6 diffuse large b-cell lymphoma 32.1 TP53 MYC MIR17 MIR155 MDM2 EZH2
7 cll/sll 32.0 TP53 SOX11 EZH2 CD5 CCND1 BTK
8 composite lymphoma 32.0 SOX11 CD5 BCL6
9 splenic marginal zone lymphoma 31.9 EZH2 CD5 BTK BCL6
10 lymphoma, mucosa-associated lymphoid type 31.9 TP53 MYC IGH CD5 CCND1 BTK
11 burkitt lymphoma 31.9 TP53 SOX11 MYC MIR155 CCND1 BMI1
12 prolymphocytic leukemia 31.8 TP53 MYC CD5 CCND1 ATM
13 b-cell lymphoma 31.7 TP53 MYC MIR17 MIR155 MDM2 MALAT1
14 autoimmune lymphoproliferative syndrome, type v 31.7 IGH CD5 BCL6
15 lymphoplasmacytic lymphoma 31.7 MIR155 IGH CD5 CCND1 BTK
16 nodal marginal zone lymphoma 31.7 IGH CD5 BCL6
17 richter's syndrome 31.7 TP53 MYC MIR17 CD5 ATM
18 adenocarcinoma 31.7 TP53 MYC MDM2 MALAT1 CCND1 BCL2
19 leukemia 31.7 TP53 MYC GAS5 CCND1 BMI1 ATM
20 retinoblastoma 31.6 TP53 MYC MDM2 MALAT1 CCNG1 CCND1
21 lymphosarcoma 31.6 IGH BCL6 BCL2
22 gastrointestinal lymphoma 31.6 CD5 CCND1 BCL6
23 b cell prolymphocytic leukemia 31.6 TP53 MYC CD5
24 mature b-cell neoplasm 31.5 TP53 MYC MIR17 MIR155 CD5 CCND1
25 prostate lymphoma 31.5 CD5 BCL6
26 myelodysplastic syndrome 31.5 TP53 MYC MDM2 EZH2 BTK BMI1
27 lymphoblastic lymphoma 31.5 TP53 MYC CD5 BCL6
28 leukemia, chronic lymphocytic 2 31.5 CD5 BCL2 ATM
29 suppression of tumorigenicity 12 31.4 TP53 MYC MDM2 EZH2 CCND1 ATM
30 plasmacytoma 31.4 MYC IGH CD5 CCND1
31 peripheral t-cell lymphoma 31.4 TP53 CD5 CCND1 BCL6
32 plasma cell neoplasm 31.3 TP53 MYC CD5 CCND1 BCL6
33 leukemia, acute myeloid 31.3 TP53 MYC MIR17 MIR155 MDM2 MALAT1
34 nodal marginal zone b-cell lymphoma 31.2 BCL6 BCL2
35 myeloma, multiple 31.2 TP53 MYC MIR17 MDM2 MALAT1 GAS5
36 acute promyelocytic leukemia 31.2 TP53 MYC MIR16-1 EZH2 CCND1 BCL6
37 reticulosarcoma 31.0 MYC IGH BCL6 BCL2
38 t-cell lymphoblastic leukemia/lymphoma 31.0 MYC MIR17 GAS5 CCND1 BCL2
39 colon lymphoma 31.0 CD5 BCL6
40 sezary's disease 31.0 TP53 MYC MIR17 CD5 BCL6
41 acquired immunodeficiency syndrome 31.0 TP53 MYC CCND1 BCL6
42 leukemia, acute lymphoblastic 31.0 TP53 MYC MIR17 MIR155 MDM2 IGH
43 hematologic cancer 31.0 TP53 MYC MIR17 MIR16-1 MIR155 CD5
44 leukemia, chronic myeloid 30.9 TP53 MYC MIR17 CCND1 BMI1 BCL2
45 t-cell acute lymphoblastic leukemia 30.9 TP53 MYC EZH2 ATM
46 pancreatic adenocarcinoma 30.9 TP53 MYC MIR155 MDM2 CCNG1 CCND1
47 lung lymphoma 30.9 CD5 BCL6
48 lung cancer susceptibility 3 30.8 TP53 MYC MIR17 MDM2 MALAT1 GAS5
49 clear cell renal cell carcinoma 30.8 TP53 MYC MIR155 MDM2 MALAT1 EZH2
50 bone lymphoma 30.8 CD5 BCL6

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to Mantle Cell Lymphoma
Sources

Symptoms & Phenotypes for Mantle Cell Lymphoma

About this section

Human phenotypes related to Mantle Cell Lymphoma:

58 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0002716
2 b-cell lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0012191
3 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
6 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
7 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
8 abnormality of bone marrow cell morphology 58 31 frequent (33%) Frequent (79-30%) HP:0005561
9 abnormality of the gastrointestinal tract 58 31 occasional (7.5%) Occasional (29-5%) HP:0011024

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ATM BCL6 CCND1 CCNG1 CD5 MDM2

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 ATM BCL2 BCL6 BTK CCND1 CCNG1
2 hematopoietic system MP:0005397 10 ATM BCL2 BCL6 BTK CCND1 CD5
3 digestive/alimentary MP:0005381 9.97 BCL2 BTK CCND1 CCNG1 MDM2 MYC
4 endocrine/exocrine gland MP:0005379 9.97 ATM BCL2 BCL6 CCND1 EZH2 MDM2
5 immune system MP:0005387 9.9 ATM BCL2 BCL6 BTK CCND1 CD5
6 integument MP:0010771 9.7 ATM BCL2 BCL6 BTK CCND1 CD5
7 neoplasm MP:0002006 9.28 ATM BCL2 BTK CCND1 CCNG1 EZH2
Sources

Drugs & Therapeutics for Mantle Cell Lymphoma

About this section

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 392)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 3
2
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
3
Idarubicin Approved Phase 3 58957-92-9 42890
4
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
5
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
6
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Ribavirin Approved Phase 3 36791-04-5 37542
9
Chlorambucil Approved Phase 3 305-03-3 2708
10
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
11
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
12
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
13
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Dalteparin Approved Phase 3 9005-49-6
16
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
17
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
18
Ofloxacin Approved Phase 3 82419-36-1 4583
19
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
22
Tazobactam Approved Phase 3 89786-04-9 123630
23
Vancomycin Approved Phase 3 1404-90-6 14969 441141
24
Piperacillin Approved Phase 3 66258-76-2 43672
25
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
26
Captopril Approved Phase 3 62571-86-2 44093
27
Palivizumab Approved, Investigational Phase 3 188039-54-5
28
Acyclovir Approved Phase 3 59277-89-3 2022
29
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
30
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
31
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
32
tannic acid Approved Phase 3 1401-55-4
33
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
34
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
35
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
36
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
37
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
38
Polyestradiol phosphate Approved Phase 3 28014-46-2
39
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
40
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
41 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
42 Interferon-alpha Phase 3
43 Interferon alpha-2 Phase 3
44 beta-Lactamase Inhibitors Phase 3
45 Amoxicillin-Potassium Clavulanate Combination Phase 3
46 Anesthetics, Dissociative Phase 3
47
protease inhibitors Phase 3
48 HIV Protease Inhibitors Phase 3
49 Neurotransmitter Agents Phase 3
50 Cytochrome P-450 Enzyme Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 1067)
# Name Status NCT ID Phase Drugs
1 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
2 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
3 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
5 Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial Unknown status NCT01933711 Phase 3 rituximab
6 A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma Unknown status NCT02354313 Phase 3 Lenalidomide
7 Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Unknown status NCT01449344 Phase 3 Rituximab;High dose Ara-C;Dexamethasone;Bortezomib
8 Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation Unknown status NCT00209209 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Fludarabine;Interferon-alpha;pegylated formula Interferon-alpha 2b
9 Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation Unknown status NCT00209222 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
10 Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination Unknown status NCT00016887 Phase 3 carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
11 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
12 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
13 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
14 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
15 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
16 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
17 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
18 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
19 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
20 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
21 Manteau 2007 SJ "LYMA" "Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL Completed NCT00921414 Phase 3 Rituximab
22 An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT00877006 Phase 3 bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
23 A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4 Completed NCT00003280 Phase 3
24 Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma Completed NCT00641095 Phase 2, Phase 3 Cyclophosphamide;Fludarabine
25 A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed NCT01646021 Phase 3 Ibrutinib;Temsirolimus
26 An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL) Completed NCT00117598 Phase 3 Temsirolimus (CCI-779);Temsirolimus (CCI-779);Investigator's choice
27 A Randomized, Open-Label, Multicenter Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant Completed NCT00722137 Phase 3 Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
28 A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT01073163 Phase 3 Bendamustine;Rituximab
29 Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas Completed NCT01456351 Phase 3 Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
30 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
31 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
32 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
33 A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma Completed NCT00269113 Phase 3 rituximab [MabThera/Rituxan];Standard chemotherapy
34 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
35 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
36 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
37 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
38 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
39 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
40 A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
41 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
42 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
43 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
44 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
45 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
46 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
47 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
48 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
49 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
50 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ibrutinib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Mantle Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
Peripheral blood stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Mantle Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells
Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743

Cochrane evidence based reviews: lymphoma, mantle-cell

Sources

Genetic Tests for Mantle Cell Lymphoma

About this section

Genetic tests related to Mantle Cell Lymphoma:

# Genetic test Affiliating Genes
1 Mantle Cell Lymphoma 29
Sources

Anatomical Context for Mantle Cell Lymphoma

About this section

MalaCards organs/tissues related to Mantle Cell Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Myeloid, Colon
Sources

Publications for Mantle Cell Lymphoma

About this section

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 4666)
# Title Authors PMID Year
1
Mantle cell lymphoma is characterized by inactivation of the ATM gene. 61 6
10706620 2000
2
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. 46 61
18483394 2008
3
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 54 61
20062012 2010
4
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. 54 61
18606985 2008
5
Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. 61 54
17488676 2007
6
[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]. 54 61
17145584 2006
7
Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. 61 54
16956411 2006
8
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. 61 54
16448697 2006
9
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. 61 54
11389032 2001
10
Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. 61 54
9846986 1998
11
Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. 54 61
9209645 1997
12
Chronic lymphoproliferative disorders. 61 54
9090492 1997
13
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. 54 61
8695815 1996
14
Mantle-cell lymphoma: classification and therapeutic implications. 61 54
9010577 1996
15
Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. 61 54
7772515 1995
16
Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. 61 54
8204893 1994
17
PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. 61 54
7918073 1994
18
Identification of genetic lesions associated with diffuse large-cell lymphoma. 61 54
8172819 1994
19
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. 61
32558897 2020
20
Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. 61
32277542 2020
21
FDG PET/CT in a Patient With Mantle Cell Lymphoma and COVID-19: Typical Findings. 61
32453077 2020
22
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. 61
32243637 2020
23
18F-FDG PET or PET/CT in Mantle Cell Lymphoma. 61
32169480 2020
24
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. 61
32170769 2020
25
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. 61
32239765 2020
26
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. 61
31537689 2020
27
Treating MCL with CAR T Cells. 61
32303507 2020
28
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. 61
32386594 2020
29
Flow cytometry in the diagnosis of mature B-cell lymphoproliferative disorders. 61
32543070 2020
30
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. 61
32511880 2020
31
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. 61
32281275 2020
32
Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level. 61
31964218 2020
33
Hematologist-Level Classification of Mature B-Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data. 61
32519455 2020
34
Subtype Distribution, Clinical Features, and Survival in B-cell Chronic Lymphoproliferative Disorders in China: A Review of 1592 Cases. 61
32220598 2020
35
The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. 61
32555407 2020
36
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. 61
31953532 2020
37
Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan. 61
32519171 2020
38
Management of Drug Resistance in Mantle Cell Lymphoma. 61
32545704 2020
39
Sister Mary Joseph nodule in mantle cell lymphoma. 61
32502460 2020
40
Emerging therapies in mantle cell lymphoma. 61
32552760 2020
41
Lymphoma of the lacrimal gland - An International Multicenter Retrospective Study. 61
32574779 2020
42
[Relationship of Expression of Circ_cgga162 with the Prognosis of Patients with Mantle Cell Lymphoma]. 61
32552951 2020
43
Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade. 61
32567674 2020
44
Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy
. 61
32213285 2020
45
CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck? 61
32516587 2020
46
QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. 61
32519202 2020
47
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. 61
31971032 2020
48
Circular RNA hsa_circ_0008285 inhibits colorectal cancer cell proliferation and migration via the miR-382-5p/PTEN axis. 61
32423803 2020
49
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. 61
32381571 2020
50
Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. 61
32125469 2020
Sources

Variations for Mantle Cell Lymphoma

About this section

ClinVar genetic disease variations for Mantle Cell Lymphoma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_001330368.2(C11orf65):c.641-20128T>CSNV Pathogenic 3039 rs121434221 11:108199926-108199926 11:108329199-108329199
2 ATM NM_001330368.2(C11orf65):c.641-20113_641-20111dupduplication Pathogenic 3040 rs796051857 11:108199908-108199909 11:108329181-108329182
3 ATM NM_000051.3(ATM):c.4081C>T (p.Gln1361Ter)SNV Pathogenic 3041 rs121434222 11:108158414-108158414 11:108287687-108287687

Cosmic variations for Mantle Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143780282 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 0

Copy number variations for Mantle Cell Lymphoma from CNVD:

7 (show all 39)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 44978 10 6600000 12200000 Loss Mantle cell lymphoma
2 49103 11 102900000 110400000 Loss ACAT Mantle cell lymphoma
3 49104 11 102900000 110400000 Loss ATM Mantle cell lymphoma
4 49105 11 102900000 110400000 Loss CUL5 Mantle cell lymphoma
5 49106 11 102900000 110400000 Loss FDX1 Mantle cell lymphoma
6 49107 11 102900000 110400000 Loss NPAT Mantle cell lymphoma
7 49108 11 102900000 110400000 Loss RAB39 Mantle cell lymphoma
8 49703 11 110400000 112500000 Loss Mantle cell lymphoma
9 49990 11 112500000 114500000 Loss TMPRSS5 Mantle cell lymphoma
10 49991 11 112500000 114500000 Loss USP28 Mantle cell lymphoma
11 49992 11 112500000 114500000 Loss ZW10 Mantle cell lymphoma
12 54401 11 43500000 48800000 Loss TP53I11 Mantle cell lymphoma
13 60881 11 92800000 97200000 Loss MAML2 Mantle cell lymphoma
14 61262 11 97200000 102100000 Loss BIRC2 Mantle cell lymphoma
15 61263 11 97200000 102100000 Loss BIRC3 Mantle cell lymphoma
16 74176 13 101700000 104800000 Loss BIVM Mantle cell lymphoma
17 74177 13 101700000 104800000 Loss ERCC5 Mantle cell lymphoma
18 74178 13 101700000 104800000 Loss KDELC1 Mantle cell lymphoma
19 74694 13 110300000 115169878 Loss C13orf11 Mantle cell lymphoma
20 74695 13 110300000 115169878 Loss C13orf17 Mantle cell lymphoma
21 74696 13 110300000 115169878 Loss CUL4A Mantle cell lymphoma
22 74697 13 110300000 115169878 Loss GRTP1 Mantle cell lymphoma
23 74698 3 117011831 117647068 Loss LAMP Mantle cell lymphoma
24 74699 13 110300000 115169878 Loss TFDP1 Mantle cell lymphoma
25 77990 13 48877883 49056026 Deletion RB1 Mantle cell lymphoma
26 79883 13 79000000 95000000 Copy number miR-17-92 Mantle cell lymphoma
27 80925 13 99300000 101700000 Loss PCCA Mantle cell lymphoma
28 118115 17 7571720 7590868 Mutation P53 Mantle cell lymphoma
29 141432 2 210288771 210598834 Deletion MAP2 Mantle cell lymphoma
30 143512 2 237300000 243199373 Loss Mantle cell lymphoma
31 170852 3 160700000 167600000 Loss SLITRK3 Mantle cell lymphoma
32 245172 9 102600000 108200000 Loss INVS Mantle cell lymphoma
33 248837 9 137400000 141213431 Loss TRAF2 Mantle cell lymphoma
34 250734 9 21967751 21994490 Deletion CDKN2A Mantle cell lymphoma
35 252714 9 36300000 38400000 Loss MELK Mantle cell lymphoma
36 254747 9 68700000 72200000 Loss TJP2 Mantle cell lymphoma
37 256309 9 91800000 93900000 Loss DIRAS2 Mantle cell lymphoma
38 256992 9 99300000 102600000 Loss GPR51 Mantle cell lymphoma
39 256993 9 99300000 102600000 Loss TBC1D2 Mantle cell lymphoma
Sources

Expression for Mantle Cell Lymphoma

About this section
Search GEO for disease gene expression data for Mantle Cell Lymphoma.
Sources

Pathways for Mantle Cell Lymphoma

About this section

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 36
Show member pathways
 12.98 TP53 MYC MDM2 CCND1 BCL2 ATM
2
Human cytomegalovirus infection 36
Show member pathways
 12.93 TP53 MYC MDM2 CCND1 BCL2 ATM
3
Endometrial cancer 36
Show member pathways
 12.86 TP53 MYC MDM2 CCND1 BCL2
4
Pathways in cancer 36
12.83 TP53 MYC MDM2 CCND1 BCL2
5
Measles 36
Show member pathways
 12.82 TP53 MYC MDM2 CCND1 BTK BCL2
6
Apoptosis Modulation and Signaling 1
Show member pathways
 12.71 TP53 MYC MDM2 BCL2 ATM
7
Chks in Checkpoint Regulation 63
Show member pathways
 12.69 TP53 MYC MDM2 CCND1 BCL2 ATM
8
Glioma 36
Show member pathways
 12.68 TP53 MDM2 CCND1 BCL2 ATM
9
ErbB signaling pathway 36 1
Show member pathways
 12.62 TP53 MYC MDM2 CCND1 BCL2
10
Mitotic G1-G1/S phases 65
Show member pathways
 12.57 TP53 MYC MDM2 CCND1 ATM
11
Apoptosis Pathway 70
Show member pathways
 12.43 TP53 MDM2 BCL2 ATM
12
Development IGF-1 receptor signaling 22
Show member pathways
 12.4 TP53 MYC MDM2 IGH CCND1
13
Shigellosis 36
12.39 TP53 MDM2 BCL2 ATM
14
Cell cycle 36 1
12.36 TP53 MYC MDM2 CCND1 ATM
15
Human T-cell leukemia virus 1 infection 36
12.34 TP53 MYC CCND1 ATM
16
Proteoglycans in cancer 36
12.3 TP53 MYC MDM2 CCND1
17
MAPK Signaling: Mitogens 64
Show member pathways
 12.23 TP53 MYC MDM2 CCND1 BCL2
18
p53 Signaling 63
Show member pathways
 12.22 TP53 MDM2 CCND1 BCL2 ATM
19
Transcriptional misregulation in cancer 36
12.22 TP53 MYC MDM2 BMI1 BCL6 ATM
20
Cellular senescence (KEGG) 36
12.12 TP53 MYC MDM2 CCND1 ATM
21
Integrated Breast Cancer Pathway 1
12.1 TP53 MYC MDM2 CCND1 BCL2 ATM
22
FoxO signaling pathway 36
Show member pathways
 12.08 MDM2 CCND1 BCL6 ATM
23
Thyroid hormone signaling pathway 36
12.03 TP53 MYC MDM2 CCND1
24
Direct p53 effectors 1
12.03 TP53 MDM2 CCNG1 BCL6 BCL2
25
Spinal Cord Injury 1
12.02 TP53 MYC CCNG1 CCND1
26
DNA Damage Response 1
Show member pathways
 11.98 TP53 MYC MIR17 MIR16-1 MDM2 CCNG1
27
Glioblastoma Multiforme 63
11.97 TP53 MYC MDM2 CCND1
28
Senescence and Autophagy in Cancer 1
11.95 TP53 MDM2 BMI1 BCL2
29
Interleukin-4 and 13 signaling 65
11.95 TP53 MYC CCND1 BCL6 BCL2
30
MicroRNAs in cancer 36
11.89 TP53 MYC MIR17 MIR16-1 MIR155 MDM2
31
Development EPO-induced Jak-STAT pathway 22
Show member pathways
 11.88 MYC BTK BCL2
32
Small cell lung cancer 36
11.87 TP53 MYC CCND1 BCL2
33
Retinoblastoma (RB) in Cancer 1
11.83 TP53 MYC MDM2 CCND1
34
ATM Pathway 63
Show member pathways
 11.82 TP53 MDM2 ATM
35
Validated targets of C-MYC transcriptional activation 1
11.79 TP53 MYC BMI1
36
C-MYB transcription factor network 1
11.77 MYC CCND1 BCL2
37
DNA Damage Response (only ATM dependent) 1
11.76 TP53 MYC MDM2 CCND1 BCL6 BCL2
38
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.74 TP53 MDM2 CCNG1 ATM
39
Platinum drug resistance 36
11.73 TP53 MDM2 BCL2 ATM
40
Bladder cancer 36 1
11.72 TP53 MYC MDM2 CCND1
41
Transcription_P53 signaling pathway 22
11.71 TP53 MDM2 BCL2 ATM
42
Regulation of Telomerase 1
11.69 MYC CCND1 ATM
43
Pathways Affected in Adenoid Cystic Carcinoma 1
11.69 TP53 MYC ATM
44
Validated targets of C-MYC transcriptional repression 1
11.65 MYC CCND1 BCL2
45
p53 pathway 1
11.61 TP53 MDM2 CCNG1 ATM
46
Copper homeostasis 1
11.59 TP53 MDM2 CCND1
47
Photodynamic therapy-induced AP-1 survival signaling. 1
11.55 TP53 CCND1 BCL2
48
Hepatitis C and Hepatocellular Carcinoma 1
11.55 TP53 MYC CCND1
49
miRNAs involved in DNA damage response 1
11.5 TP53 MYC MIR16-1 CCND1 ATM
50
Integrated Cancer Pathway 1
11.43 TP53 MYC MDM2 BCL2 ATM
Sources

GO Terms for Mantle Cell Lymphoma

About this section

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.36 TP53 SOX11 MYC MDM2 EZH2 CCNG1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.08 TP53 MYC MDM2 BCL6 BCL2
2 positive regulation of cell proliferation GO:0008284 10.04 SOX11 MYC MDM2 EZH2 CCND1 BCL2
3 regulation of gene expression GO:0010468 10.02 MYC MDM2 EZH2 BMI1 BCL2
4 response to drug GO:0042493 9.99 TP53 MYC MDM2 CCND1 BCL2
5 cellular response to DNA damage stimulus GO:0006974 9.97 TP53 MYC CCND1 BCL6 BCL2 ATM
6 regulation of cell proliferation GO:0042127 9.96 TP53 MIR155 EZH2 BCL6
7 cytokine-mediated signaling pathway GO:0019221 9.95 TP53 MYC CCND1 BCL6 BCL2
8 positive regulation of gene expression GO:0010628 9.93 TP53 SOX11 MYC MIR155 MDM2 ATM
9 negative regulation of transcription by RNA polymerase II GO:0000122 9.92 TP53 SOX11 MYC MDM2 EZH2 CCND1
10 regulation of apoptotic process GO:0042981 9.88 TP53 MIR155 BCL6 BCL2 ATM
11 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.83 MIR16-1 EZH2 BCL2
12 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.82 TP53 MDM2 ATM
13 ovarian follicle development GO:0001541 9.79 MYC BCL2 ATM
14 neuron apoptotic process GO:0051402 9.79 TP53 BCL2 ATM
15 positive regulation of cell cycle GO:0045787 9.78 MYC MDM2 CCND1
16 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.77 TP53 MIR16-1 BCL2
17 negative regulation of mitotic cell cycle GO:0045930 9.76 TP53 MIR16-1 BCL2
18 cellular response to organic substance GO:0071310 9.75 MDM2 CCND1 BCL2
19 liver regeneration GO:0097421 9.71 MYC EZH2 CCND1
20 response to steroid hormone GO:0048545 9.7 MDM2 CCND1 BCL2
21 positive regulation of response to DNA damage stimulus GO:2001022 9.69 MYC ATM
22 cellular response to gamma radiation GO:0071480 9.69 TP53 MDM2 ATM
23 positive regulation of connective tissue replacement GO:1905205 9.68 MIR16-1 MIR155
24 cardiac septum morphogenesis GO:0060411 9.68 TP53 MDM2
25 replicative senescence GO:0090399 9.68 TP53 ATM
26 oocyte development GO:0048599 9.67 BCL2 ATM
27 response to magnesium ion GO:0032026 9.67 MDM2 CCND1
28 positive regulation of histone deacetylation GO:0031065 9.67 TP53 BCL6
29 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.66 MIR17 MIR155
30 mitotic G1 DNA damage checkpoint GO:0031571 9.65 TP53 CCND1
31 cellular response to UV-C GO:0071494 9.65 TP53 MDM2
32 regulation of cell cycle GO:0051726 9.65 TP53 CCNG1 CCND1 BCL2 ATM
33 T cell lineage commitment GO:0002360 9.64 TP53 BCL2
34 re-entry into mitotic cell cycle GO:0000320 9.63 MYC CCND1
35 B cell lineage commitment GO:0002326 9.63 TP53 BCL2
36 response to gamma radiation GO:0010332 9.61 TP53 MYC BCL2
37 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.58 TP53 MIR17 MIR16-1
38 cellular response to actinomycin D GO:0072717 9.56 TP53 MDM2
39 response to iron ion GO:0010039 9.54 MDM2 CCND1 BCL2
40 negative regulation of gene expression GO:0010629 9.5 TP53 SOX11 MYC MIR17 MIR155 MDM2
41 positive regulation of fibroblast proliferation GO:0048146 9.46 MYC MIR17 MIR155 BMI1
42 cellular response to hypoxia GO:0071456 9.17 TP53 MYC MIR17 MIR155 MDM2 MALAT1

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 promoter-specific chromatin binding GO:1990841 8.8 TP53 EZH2 BMI1
Sources

Sources for Mantle Cell Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....